Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 6 results
Author [ Title(Desc)] Type Year
Filters: Keyword is Immunosuppressive Agents  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Persley K, Scherl E, Rubin P.  2001.  Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis.. Am J Gastroenterol. 96(12):3444-5.
E
Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H et al..  2019.  Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.. Inflamm Bowel Dis. 25(4):775-781.
M
Steinlauf AF, Present DH.  2004.  Medical management of the pregnant patient with inflammatory bowel disease.. Gastroenterol Clin North Am. 33(2):361-85,xi.
P
Ghosh G, Jacob V, Wan D.  2018.  Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.. Clin Gastroenterol Hepatol. 16(4):e41-e42.
Poppers DM, Scherl EJ.  2008.  Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.. Inflamm Bowel Dis. 14(1):106-13.
R
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.  2008.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.